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Introduction: Intra-articular injection of hyaluronic acid (HA) is often used as therapy for knee osteoarthritis
because it is less expensive and less aggressive than total knee replacement. Therefore, it is important to document
whether HA is safe and efficacious. We tested whether single and multiple injection viscosupplementation with HA
is associated with clinically meaningful pain relief in a new randomized clinical trial (RCT). Our objective was to
compare safety and efficacy of intra-articular HA in two formulations: one 3.0 ml injection of Durolane versus five
2.5 ml injections of Artz for the treatment of knee osteoarthritis pain.
Methods: Patients (N = 349) from the People’s Republic of China were randomized to treatment (Durolane = 175,
Artz = 174). The Durolane group received a 3.0 ml injection at week 0 (baseline), with sham skin punctures at weeks
1, 2, 3, and 4. The Artz group received one 2.5 ml injection at each of the same time points. The primary assessment
tool was the Likert-type Western Ontario and McMaster University (WOMAC) pain scale at weeks 0, 6, 10, 14, 18, and 26.
Secondary assessments were WOMAC physical function, knee stiffness, and global self-assessment, at identical time
points. Statistically-controlled analyses were non-inferiority of Durolane over 18, then over 26 weeks, with a priori
non-inferiority defined as 8% of the relevant scale. Acetaminophen was permitted as rescue analgesia and all adverse
events (AEs) were recorded.
Results: Overall study retention was excellent; 332 patients (95.1%) completed 18 weeks and 319 (91.4%) completed
26 weeks, with no significant retention difference between treatment arms. All variables met non-inferiority criteria over
18 and 26 weeks. Efficacy response in both arms was >90%. Treatment-related AEs were 9.8% (17/174) for Artz and
13.1% (23/175) for Durolane.
Conclusions: A single injection of Durolane is non-inferior to 5 injections of Artz over 18 and 26 weeks for pain,
physical function, global self-assessment, and knee stiffness. Both treatments were efficacious, safe, and well tolerated.
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Knee osteoarthritis (OA) is a degenerative joint disease
that caused moderate to severe disability in 43.4 million
people globally in 2004 [1]. Aggregate economic costs
are considerable because treatment is not curative [2];
current treatment focuses on relieving pain and other
symptoms, as well as improving function [3,4].
Intra-articular injection of hyaluronic acid (HA) is
widely used as therapy because: it is less aggressive [5] and
less expensive [5-9] than total knee replacement; HA has
fewer and generally less serious adverse events (AEs) than
total knee replacement [10,11]; and HA is documented to
provide treatment efficacy [12-19]. Nevertheless, a recent
meta-analysis concluded that ‘In patients with knee osteo-
arthritis, viscosupplementation is associated with a small
and clinically irrelevant [pain] benefit and an increased
risk for serious adverse events’ [20]. We seek to test
whether single-injection and multiple-injection viscosup-
plementation is associated with clinically meaningful pain
relief in a new randomized clinical trial (RCT).
Our goal was to test for non-inferiority of two formula-
tions of HA in treatment of knee OA over an 18-week and
then over a 26-week time period. We contrast Durolane
(Q-med AB, Sweden), a stabilized HA that is obtained
from a nonanimal source, with Artz (also marketed under
the names Artzal and Supartz; Seikagaku Corporation
Japan), a noncross-linked (native) animal-derived HA that
has been available on the Chinese market since 1997.
Methods
Overview
We report a multicenter, randomized, double-blind, 26-
week non-inferiority trial comparing intra-articular injec-
tion of Durolane (one dose plus four sham injections) with
intra-articular Artz (five doses) in the treatment of knee
pain among adults clinically diagnosed with mild-to-
moderate knee OA.
The institutional review board or ethics committee for
each study site (see Acknowledgements) was responsible
for review and approval of the clinical study, in accord-
ance with guidelines of the International Conference on
Harmonization, as well as any local regulatory require-
ments of each site. Written approval of the protocol,
amendments, and the patient informed consent form
were submitted to Bioventus LLC (Durham, NC, USA)
before study drugs were shipped to each site.
Subjects were recruited consecutively at any of seven hos-
pitals between January 2011 and February 2012, a period of
approximately 1 year. Each potential subject provided written
informed consent and underwent a qualifying screening
examination prior to study enrollment. Each patient
consented that their study data could be examined by the
sponsor, drug regulatory authorities, auditors, and study mo-
nitors, in compliance with the statement of confidentiality.After consent, eligible subjects were allocated ran-
domly to either Durolane or Artz. Randomization was
double-blinded, using a 1:1 allocation in block sizes of
four patients. The allocation schedule was generated by
statisticians at TigerMed Consulting Co., Ltd (Beijing,
China), using SAS Proc Plan (v9.1.3; Cary, NC).
Patients
Patients were recruited for the study from seven sites in
the People’s Republic of China (Beijing, four hospitals;
Shanghai, two hospitals; Hangzhou, one hospital). Assess-
ment at screening included a radiograph of the study knee
in the standing, weight-bearing, semi-flexed, postero-
anterior view, as assessed by the X-ray reader assigned to
each study center. Inclusion criteria were as follows: males
or females, age 40 to 80 years; physician diagnosis of mild-
to-moderate OA fulfilling American College of Rheuma-
tology criteria [21], as recorded in the chart; radiographic
evidence of OA (Kellgren–Lawrence radiographic score
of 2 or 3); Western Ontario and McMaster University
(WOMAC) Likert pain subscore of 7 to 17 at both screen-
ing and baseline visits; and WOMAC Likert pain question
score of 2 to 3 while walking on a flat surface.
Patient exclusion criteria were: clinically apparent tense
effusion on physician examination, determined by either a
positive bulge sign or positive ballottement of the patella;
Kellgren-Lawrence radiographic score of 0, 1, or 4 in the
study knee; symptomatic OA of the contralateral knee (or
of either hip) that is not responsive to acetaminophen
and/or that requires any change in physical therapy;
WOMAC Likert pain question score >3 in the contralateral
(nonstudied) knee; intra-articular injection of any HA in
the study knee within 9 months prior to screening; previ-
ous allergic reaction to any HA product; intra-articular in-
jection of corticosteroids in any joint within 6 months prior
to screening; treatment with glucosamine–chondroitin
sulfate supplement initiated within the past 3 months, or
dosage not stable for the past 3 months; active skin disease
or infection at the injection site; active hepatic disease, ab-
normal liver function (Alanine transaminase, Aspartate
transaminase or Total bilirubin level more than twice nor-
mal values), or renal dysfunction (blood creatinine over
the upper limit of normal); systemic inflammatory condi-
tions, autoimmune diseases, connective tissue diseases
(including rheumatoid arthritis, inflammatory arthritis, an-
kylosing spondylitis, psoriatic arthritis, reactive arthritis,
gout/acute pseudo-gout), or uncontrolled hypothyroidism;
bleeding diathesis or use of anticoagulants (except aspirin
<325 mg/day); and any other medical condition that might
make the patient unsuitable for study (for example, any
musculoskeletal condition impeding measurement of
efficacy at the studied knee, severe progressive chronic
disease, malignancy, bleeding disorder, fibromyalgia,
significant venous or lymphatic stasis).
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Treatment procedures for both products were identical.
After screening, patients were given a 2-week washout
period for analgesics other than acetaminophen. At week
0, patients were randomized 1:1 and received their first
injection of either Durolane or Artz. Injections followed
at weeks 1, 2, 3, and 4. For the Durolane arm, all subse-
quent injections were sham injections; for the Artz arm,
all injections were active. Sham injections of Durolane
were subcutaneous and used an empty syringe, and the
needle did not enter the joint space. Subcutaneous sham
needles have proven indistinguishable from deeper nee-
dles in clinical trials of acupuncture [22].
Disinfectants containing quaternary ammonium salts
such as benzalkonium chloride, which can induce HA
precipitation, were avoided. Anesthetization of the injec-
tion site was permitted using a topical anesthetic (for ex-
ample, ethyl chloride or lidocaine spray).
Patient blinding was achieved by draping, so that patients
could not determine by sight how the injection was given
or what product was injected. Patients were also told that
each injection could feel different, to minimize the placebo
effect in the Durolane arm. Physicians who gave injections
could not be blinded, but outcome assessment was done by
different physicians blind to the study treatment.
Physicians were allowed to inject HA at the knee portal
with which they were most experienced (lateral upper pa-
tellar, lateral mid patellar, or medial mid patellar). Needles
(sizes 20 G and 22 G) were supplied to each study site and
unblinded personnel chose the appropriate needle. Joint
fluid was withdrawn using an empty 20 ml syringe and
the volume of aspirated fluid was recorded. Leaving the
needle in place, the syringe was removed and replaced by
a prefilled Durolane or Artz syringe. Care was taken when
exchanging syringes to avoid displacement of the needle
and to ensure that the syringe with the study product was
securely attached prior to injection.
Efficacy assessments
The only permitted rescue medication for pain was acet-
aminophen, at doses up to 4 g daily. Efficacy assessments
were collected at weeks 0 (baseline), 6, 10, 14, 18, and 26.
The 18-week follow-up period was the primary efficacy
assessment period. Efficacy assessments included the Likert-
type WOMAC pain scale (range 0 to 20, higher scores bet-
ter), with physical function (range 0 to 68) and knee function
(range 0 to 8) subscales [23]. The WOMAC translation into
Chinese has been validated in Chinese patients [24]. Global
self-assessment scores (range 0 to 10, lower scores better)
and total grams of acetaminophen used were also collected.
Safety
AE reports were collected continuously, physical exami-
nations and vital signs were assessed at week 0 and 26,and electrocardiograms and blood and urine laboratories
were assessed at weeks 0 and 10.
Statistical methods
Three datasets were defined for analysis. The intention-
to-treat (ITT) set included all patients randomized. The
safety set included all patients who received treatment.
The per-protocol set included ITT patients who com-
pleted all scheduled treatments and also completed all
WOMAC pain subscale assessments through week 18,
without any major protocol deviations. The per-protocol
set was used to assess non-inferiority; since all patients
received all treatments and had minimal protocol devia-
tions, this should maximize the difference between treat-
ment arms, if a difference truly exists.
The primary efficacy variable was the WOMAC pain sub-
scale change from baseline (CFB). Secondary efficacy vari-
ables were the WOMAC physical function subscale CFB,
the global self-assessment CFB, and the WOMAC knee stiff-
ness subscale CFB. All other efficacy variables assessed were
exploratory, including the Outcome Measures in Rheuma-
toid Arthritis Clinical Trials – Osteoarthritis Research
Society International (OMERACT-OARSI) responder vari-
able [25] and use of rescue medications. Exploratory sub-
groups were split by gender, age (cutoff point >50 years old),
and Kellgren–Lawrence grade II and III at baseline.
Important AEs resulted in a dose adjustment, interrup-
tion, or permanent stop. AEs were defined as treatment-
emergent adverse events (TEAEs) or treatment-related
adverse events (TRAEs). TEAEs included all medical
events reported after the first treatment. TRAEs were
judged by the site investigator to have a definite, possible,
or uncertain relationship to treatment. Both TEAEs and
TRAEs were reported, including events classified by the
investigator as possibly, probably, or definitely treatment
related. Vital signs, blood, and chemistry laboratories were
used to study the CFB. Laboratory values and electrocar-
diograms were also used to study shifts from baseline.
The required sample size was calculated under several
assumptions for the WOMAC pain subscale; change
standard deviation is 20 mm with a non-inferiority mar-
gin of +8 mm [26] (8% on the 100 mm visual analog
scale), which is +1.6 on a Likert 0 to 20 scale, with a type
I error rate of 0.05 and a type II error rate of 0.10. The
required sample size under these assumptions was 132
per arm, for a total of 264 patients. To account for an an-
ticipated 25% loss to follow-up and important protocol de-
viations, the recruited sample size was increased to 175
per arm, for a final total of 350 patients.
Although the study sample size was based on the
WOMAC pain scale, we also evaluated WOMAC phys-
ical function, knee stiffness, and global self-assessment
in a stepwise manner to control overall type I error at
0.05. Non-inferiority tests used 8% margins of the
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knee stiffness, +0.64; and global self-assessment, −0.80.
Non-inferiority hypotheses were tested using mixed-
effects repeated-measures models. Primary and secondary
variables were fitted to mixed-effects repeated-measures
regressions, with subscale CFB the dependent variable.
Subject baseline assessment, study site, treatment, visit,
and treatment-by-visit interactions were fixed effects,
patients were the random effect, and degrees of freedom
were calculated by an established method [27]. Non-
inferiority was concluded if the upper bound of the
(Durolane – Artz) 95% confidence interval was less than
the non-inferiority margin; or, in the case of the patient
global self-evaluation, if the lower bound was greater
than this margin.
Because non-inferiority hypothesis testing was carried
out over two time periods (18 and 26 weeks) and for
four assessments (a primary aim for pain and secondary
aims for physical function, global self-assessment, and
knee stiffness), it was necessary to predefine test order
to control for overall type I error. The pain primary vari-
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Figure 1 CONSORT flow chart for subjects who were enrolled in the Conon-inferiority was concluded, then non-inferiority was
tested again over 26 weeks. Physical function was then
tested in the same manner, followed by subject global
self-assessment, and finally knee stiffness. If any individ-
ual test failed to conclude non-inferiority, then subse-
quent hypothesis tests for non-inferiority would not
qualify as controlled for type I error.
Exploratory responder variables were analyzed using
generalized estimable equation regressions with corre-
sponding explanatory variables. No formal type I error-
controlled hypothesis testing was planned.
Study results were audited by TigerMed Consulting Co.,
Ltd, evaluating each research site and assessing compli-
ance to the clinical trial protocol. Site visits included a
random audit of patient records, and a study report was
filed at the People’s Hospital of Beijing University and at
Bioventus LLC. TigerMed Consulting Co., Ltd was also
responsible for data management and statistical analysis.
Results
A total of 404 patients were screened and 349 (86.4%) pa-
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mparison of Hyaluronic Acids for Safety and Efficacy (CHASE) Trial.
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protocol set analysis. Baseline demographics and clinical
characteristics (Table 1) were balanced between treatment
arms. Overall, 97.8% of patients were Han Chinese and
75.2% of patients were naive to any treatment.Table 1 Demographics and baseline clinical
characteristics (per-protocol set)
Artz Durolane
(n = 158) (n = 161)
Age (years)
Number 158 161
Mean (standard deviation) 60.4 (7.75) 60.2 (8.06)
Minimum; maximum 42; 78 40; 78
Sex (female) 127 (80.4) 119 (73.9)
Body mass index classification
Underweight 0 (0.0) 1 (0.6)
Normal range 76 (48.1) 81 (50.3)
Overweight 69 (43.7) 65 (40.4)
Obese 13 (8.2) 14 (8.7)
Duration of disease (months)
Number 157 161
Mean (standard deviation) 47.7 (57.59) 47.2 (63.15)
Median 22.2 17.6
ACR criteria
Significant knee pain most days
during the last 3 months
158 (100%) 161 (100%)
Age >50 years 147 (93.0%) 147 (91.3%)
Morning stiffness <30 minutes 129 (81.6%) 127 (78.9%)
Crepitus on motion 141 (89.2%) 148 (91.9%)
Surgical history
Intra-articular steroid injection 5 (3.2%) 5 (3.1%)
Intra-articular hyaluronic acid injection 28 (17.7%) 36 (22.4%
Arthroscopy and/or other surgical
procedure
8 (5.1%) 4 (2.5%)
No treatment 122 (77.2%) 118 (73.3%)
X-ray examination
II: definite osteophyte, unimpaired
joint space
95 (60.1%) 94 (58.4%)
III: moderate diminution of joint space 63 (39.9%) 67 (41.6%)
Likert-type WOMAC subscalesa
Pain (range 0 to 20) 9.5 (1.80) 9.4 (1.98)
Physical function (range 0 to 68) 22.7 (8.00) 22.3 (8.38)
Knee stiffness (range 0 to 8) 3.1 (1.77) 2.8 (1.73)
Global self-assessmentb (range 0 to 10) 4.3 (2.06) 4.3 (1.97)
Data presented as number, n (%) or mean (standard deviation) unless stated
otherwise. Durolane from Q-med AB (Sweden) and Artz from Seikagaku
Corporation (Japan). ACR, American College of Rheumatology; WOMAC,
Western Ontario McMasters University Osteoarthritis Index. aLower scores
better. bHigher scores better.The primary analysis over 18 weeks showed that
Durolane was non-inferior to Artz in terms of pain con-
trol; this was also true over 26 weeks (Table 2). All second-
ary efficacy variables were tested over week 18 and week
26, and Durolane was non-inferior to Artz in all compari-
sons. Mixed-effects repeated-measures results are shown
by week 18 and by week 26 (Table 2).
Patients responded well to both Durolane and Artz
(Table 3); however, there were twice as many nonre-
sponders with Durolane in the WOMAC pain ‘walking
on a flat surface’ variable. Rescue medication use was
comparable between treatment arms; acetaminophen use
did not differ between the two patient groups (Table 4),
and no more than 16% of patients used rescue medication
at any time (Table 4).
When efficacy analyses were repeated using the ITT
set, all conclusions were identical. In the subgroup ana-
lyses (gender, age, and Kellgren–Lawrence grade II and
III at baseline) there were no statistically detectable or
clinically relevant differences.
The incidence of AEs was similar in patients receiving
Durolane or Artz (Table 5). The three most common
TEAEs were arthralgia (14.9% and 16.7%, for Durolane
and Artz respectively), upper respiratory tract infection
(7.4% and 4.6%), and injection site pain (4.0% and 3.4%).
Among nine patients reporting serious AEs, none were
judged to be treatment related. TRAEs affected 13.1% of
Durolane patients and 9.8% of Artz patients. The most
common TRAE was arthralgia followed by joint swelling,
and TRAEs related to the study knee were balanced be-
tween study arms. Severity in both groups was mainly
mild to moderate (one injection site pain in the Durolane
group was considered severe; two cases of arthralgia and
one case of joint swelling in the Artz group were con-
sidered severe). The incidence of serious AEs was 1.7%
(3/175) and 3.4% (6/174) in the Durolane and Artz
groups, respectively, and no serious AE was related to
the investigational products, as judged by the investiga-
tors. No death occurred in this study. Vital signs, blood
chemistry and urine laboratories, and electrocardiogram
results yielded no clinically relevant safety outcomes or
treatment group differences.
Discussion
We report a non-inferiority trial of Durolane (one injec-
tion) versus Artz (five injections) over 18 and 26 weeks.
Patients were well matched at baseline (Table 1) and
study retention was excellent (Figure 1). Both treatment
groups showed a clinically significant, identical, and ro-
bust response to treatment, for the primary aim of pain
(Table 2), for secondary aims of physical function, global
self-assessment, and knee stiffness (Table 2), and for ex-
ploratory responder variables (Table 3). Use of rescue
medications was low (Table 4), and both Durolane and
Table 2 Non-inferiority variables: mixed-effects repeated-measures results, weeks 18 and 26 (per-protocol set)
Change from baseline Treatment-related
Artz Durolane difference
(5 × 2.5 ml) (1 × 3 ml, 4 × sham) (Durolane – Artz)
(n = 158) (n = 161)
Paina
Week 18
LSM (95% CI) −5.87 (−6.23; −5.52) −5.97 (−6.32; −5.61) −0.09 (−0.58; 0.39)
P value <0.0001 <0.0001 0.7034
Week 26
LSM (95% CI) −6.05 (−6.39; −5.71) −6.15 (−6.49; −5.81) −0.10 (−0.56; 0.37)
P value <0.0001 <0.0001 0.6783
Physical functiona
Week 18
LSM (95% CI) −12.10 (−12.95; −11.26) −12.75 (−13.60; −11.91) −0.65 (−1.81; 0.51)
P value <0.0001 <0.0001 0.2718
Week 26
LSM (95% CI) −12.58 (−13.39; −11.77) −13.16 (−13.97; −12.35) −0.58 (−1.69; 0.53)
P value <0.0001 <0.0001 0.3054
Global evaluationb
Week 18
LSM (95% CI) 2.55 (2.33; 2.77) 2.70 (2.48; 2.92) 0.15 (−0.15; 0.45)
P value <0.0001 <0.0001 0.3319
Week 26
LSM (95% CI) 2.67 (2.45; 2.88) 2.81 (2.59; 3.02) 0.14 (−0.16; 0.43)
P value <0.0001 <0.0001 0.3583
Knee stiffnessa
Week 18
LSM (95% CI) −1.73 (−1.87; −1.59) −1.87 (−2.00; −1.73) −0.14 (−0.33; 0.05)
P value <0.0001 <0.0001 0.1602
Week 26
LSM (95% CI) −1.80 (−1.93; −1.67) −1.95 (−2.08; −1.82) −0.15 (−0.33; 0.03)
P value <0.0001 <0.0001 0.1012
Durolane from Q-med AB (Sweden) and Artz from Seikagaku Corporation (Japan). CI, confidence interval; LSM, ???. aA negative change from baseline is an improvement.
bA positive change from baseline is an improvement.
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results provide rigorous evidence that Durolane is non-
inferior to Artz; both Artz and Durolane are safe, effica-
cious, and well tolerated.
Patients responded comparably well to Durolane and
Artz (Table 3). However, there were statistically more
nonresponders at weeks 18 and 26 with Durolane in the
WOMAC pain ‘walking on a flat surface’ item, although
there were few nonresponders overall (Table 3). Con-
versely, there were numerically more nonresponders with
Artz according to the OMERACT-OARSI criteria, al-
though this difference did not attain statistical significance
(Table 3). This discrepancy between measures may be afunction of the small number of nonresponders and a
large sample size.
Use of rescue medication by patients was quite low
overall (Table 4). Only 14% of patients used rescue medi-
cation within 4 to 6 weeks of treatment, and roughly 5%
of patients used rescue medication during weeks 10 to 18
(Table 4). Low use of rescue medication is consistent with
the high perceived efficacy of treatment in reducing pain
(Table 2), even at weeks 18 and 26. After week 18, use of
rescue medication began to increase, perhaps as a result
of loss of efficacy of both products with time (Table 4). A
similar study in Germany, which used Euflexxa versus
Synvisc in the treatment of knee OA, reported that 49.3%
Table 3 Responder variables, weeks 18 and 26
(per-protocol set)
Visit (week) Artz Durolane Odds ratio
(95%CI)(5 × 2.5 ml) (1 × 3 ml, 4 × sham)
(n = 158) (n = 161) P value
OMERACT-OARSI
Week 18
Responder 146 (92.4%) 152 (94.4%) 1.15 (0.63; 2.09)
Nonresponder 12 (7.6%) 9 (5.6%) 0.6487
Week 26
Responder 148 (93.7%) 151 (93.8%) 1.12 (0.61; 2.05)
Nonresponder 10 (6.3%) 10 (6.2%) 0.7129
WOMAC pain subscale
Week 18
Responder 116 (73.4%) 124 (77.0%) 0.91 (0.62; 1.35)
Nonresponder 42 (26.6%) 37 (23.0%) 0.6473
Week 26
Responder 129 (81.6%) 127 (78.9%) 0.96 (0.65; 1.41)
Nonresponder 29 (18.4%) 34 (21.1%) 0.8157
WOMAC pain ‘walking on a flat surface’ item
Week 18
Responder 152 (96.2%) 149 (92.5%) 2.12 (1.14; 3.94)
Nonresponder 6 (3.8%) 12 (7.5%) 0.0176
Week 26
Responder 153 (96.8%) 148 (91.9%) 2.26 (1.23; 4.12)
Nonresponder 5 (3.2%) 13 (8.1%) 0.0082
Data presented as n (%). Odds ratio obtained from a generalized estimable
equation model. Durolane from Q-med AB (Sweden) and Artz from Seikagaku
Corporation (Japan). CI, confidence interval; OMERACT-OARSI, Outcome
Measures in Rheumatoid Arthritis Clinical Trials – Osteoarthritis Research
Society International; WOMAC, Western Ontario and McMaster University.
Table 4 Summary of rescue medication use-total grams
used by visit (per-protocol set)
Time interval Statistic Artz Durolane
(5 × 2.5 ml) (1 × 3 ml, 4 × sham)
(n = 158) (n = 161)
Pre treatment n (%) 2 (1.3%) 4 (2.5%)
Mean (SD) 1.25 (0.35) 1.25 (0.87)
Median 1.25 1.00
Week 4 to week 6 n (%) 20 (12.7%) 26 (16.1%)
Mean (SD) 4.48 (5.81) 4.75 (5.41)
Median 2.00 2.75
Week 6 to week 10 n (%) 13 (8.2%) 14 (8.7%)
Mean (SD) 3.12 (3.90) 4.14 (6.13)
Median 1.50 1.50
Week 10 to week 14 n (%) 10 (6.3%) 6 (3.7%)
Mean (SD) 2.75 (3.83) 3.58 (3.76)
Median 1.00 2.25
Week 14 to week 18 n (%) 9 (5.7%) 5 (3.1%)
Mean (SD) 4.56 (6.05) 2.60 (2.30)
Median 1.50 2.50
Week 18 to week 26 n (%) 21 (13.3%) 17 (10.6%)
Mean (SD) 6.10 (6.28) 6.26 (6.94)
Median 3.50 3.50
Only patients that used rescue medication were included. Durolane from
Q-med AB (Sweden) and Artz from Seikagaku Corporation (Japan). SD,
standard deviation.
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Synvisc required rescue medication at some point during
the trial [26].
Incidence of TEAEs was similar between the Durolane
(47.5%) and Artz (42.5%) treatment groups (Table 5),
consistent with similar knee HA trials [26,28-30]. A trial
of different forms of HA reported that 37.1% of patients
(119 of 321) experienced TEAEs, all of mild-to-moderate
intensity [26], while a similar trial of two HAs reported
that 55.0% of patients (326 of 588) experienced TEAEs
[30]. TRAEs were less prevalent than TEAEs. Arthralgia
was the common TRAE here (Table 5) and arthralgia is
expected among patients who receive HA injections
[29]. Our results suggest that a single Durolane injec-
tion for treatment of OA knee pain was safe and well
tolerated.
The conclusion that Durolane is non-inferior to Artz
is robust, as all four indications more than satisfied 8%
non-inferiority criteria (Table 2). We report that theWOMAC pain response rate (Durolane + Artz) averaged
75.2% at week 18 and 80.3% at week 26 (Table 3), which
is an unusually high response rate. In contrast, a RCT of
HAs versus saline found that the WOMAC pain re-
sponse rate to HA was 38.1% at week 13 and 36.3% at
week 26 [28]. The OARSI response rates we report are
also higher than is generally reported. For both Durolane
and Artz, the OMERACT-OARSI response rate was at
least 92% at weeks 18 and 26 (Table 3). One RCT of
HAs versus steroid reported the OARSI response rate to
HA was 63.3% at week 18 and 62.8% at week 26 [29]. The
OARSI response rate to HA in a second RCT was 66% at
week 12 and 67% at week 26 [30]. In a RCT with un-
usually long follow-up, the OARSI response rate to HAs
ranged from 71.1% at 7 months to 80.5% at 40 months
[31]. It is unclear how best to explain the strength of our
results, although there are several possibilities.
It may be typical that Chinese patients respond well to
HAs. To our knowledge, only four prior RCTs have been
carried out in China to test HAs in treatment of knee
OA, so we have no a priori expectations as to the ro-
bustness of expected responses. For example, HAs were
compared with warm acupuncture [32] and with electro-
acupuncture [33], and both studies documented a good
Table 5 Summary of treatment-emergent/treatment-
related adverse events (safety set)
Adverse event category Artz Durolane
(5 × 2.5 ml) (1 × 3 ml, 4 × sham)
(n = 174) (n = 175)
Patients with at least one treatment-
emergent adverse event
74 (42.5%) 83 (47.4%)
Treatment-related adverse event 17 (9.8%) 23 (13.1%)
Treatment adjustment 1 (0.6%) 0
Treatment permanent stop 1 (0.6%) 0
Importanta 2 (1.1%) 0
Severe 8 (4.6%) 6 (3.4%)
Seriousb 6 (3.4%) 3 (1.7%)
All treatment-related adverse eventsc 17 (9.8%) 23 (13.1%)
Musculoskeletal and connective
tissue disorders
16 (9.2%) 18 (10.3%)
Arthralgia 13 (7.5%) 15 (8.6%)
Joint swelling 3 (1.7%) 3 (1.7%)
Arthropathy 0 1 (0.6%)
Epicondylitis 1 (0.6%) 0
Joint effusion 0 1 (0.6%)
Limb discomfort 1 (0.6%) 0
Muscular weakness 0 1 (0.6%)
Musculoskeletal discomfort 0 1 (0.6%)
Myalgia 1 (0.6%) 0
Pain in extremity 0 1 (0.6%)
Skin and subcutaneous tissue
disorders
0 1 (0.6%)
Erythema 0 1 (0.6%)
Data presented as number (%). Patients who experienced more than one
adverse event are counted once in each row. Durolane from Q-med AB
(Sweden) and Artz from Seikagaku Corporation (Japan). aAn important adverse
event is any nonsevere adverse event leading to dose adjustment, interruption,
or permanent stop. bNone of the serious adverse events were reported to be
treatment related. cTreatment-related adverse events were judged to have a
definite, possible, or uncertain relationship to treatment.
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[33], response to HA was comparable in magnitude with
what we report; patients with stage II Kellgren–Lawrence
scores showed a decline in total symptom scores from
12.2 to 6.5 over 5 weeks. Another Chinese study com-
pared HA with glucosamine sulfate or to a combination of
glucosamine sulfate and arthroscopic debridement [34],
and this study found that all treatments were efficacious.
A final study compared HA with meloxicam in adult pa-
tients with Kashin–Beck disease, a chronic osteochon-
dropathy largely limited to China [35]. In this study,
patient improvement from baseline in the WOMAC A
(pain) score was 4.6 points over 12 weeks, among 80 pa-
tients who had HA (25 mg) injected into the target knee
at weekly intervals for 3 weeks [35]. The WOMAC A
score was 12.5 at baseline and 7.9 at week 12, for anaverage improvement of 4.6 points [35]. In our study,
the WOMAC A score was 9.5 at baseline (Table 1) and
improved by an average of 5.9 points over 18 weeks
(Table 2). Hence, our results show roughly comparable
pain relief in OA patients with those in patients with
Kashin–Beck disease [35].
Most patients were naïve to any treatment before
study enrollment (Table 1), and analgesic use in China is
low overall compared with the United States [36]. It is
therefore possible that patients benefitted from initiation
of treatment or from encouragement to use analgesics
for pain control. Nevertheless, analgesic use overall was
quite low (Table 4). There can be ethnic differences in
how efficiently acetaminophen is metabolized; such dif-
ferences in susceptibility to pain alleviation [37] could
potentially explain low use of analgesics in our study
(Table 4). In addition, metabolism of acetaminophen is
affected by gender, oral contraceptive use, and smoking
[38] and such factors can differ from study to study.
Acetaminophen glucuronidation is higher in males than
in females, such that male smokers have the highest rate
and female nonsmokers or noncontraceptive users have
the lowest rate of glucuronidation [38].
Ethnic differences in pain sensitivity have been docu-
mented [39-43], and such differences could potentially
result in clinically significant differences in reported
pain. Little is known about whether documented experi-
mental differences in the thermal pain threshold might
influence patient willingness to rehabilitate aggressively
or to abstain from use of rescue medications.
A criticism of our work is that we did not use an in-
active placebo arm, so it is unclear how much of the
documented efficacy (Tables 2, 3, and 4) can be attrib-
uted to a placebo response. Placebo arms have been rec-
ommended even in surgical RCTs, and improvement in
the placebo arm was documented in 39 of 53 surgical
RCTs [44]. The majority of past HA trials have used
placebo – defined as saline injection or arthrocentesis of
the joint space – and the conclusion is broadly that HAs
are superior to placebo [45]. However, neither saline in-
jection nor arthrocentesis is truly inactive [46], and sub-
cutaneous placebos are known to be more effective than
oral placebos [47]. The alternative to inactive placebo is
to compare a new medication with the best current
medication, accepting that such comparator trials may
produce higher placebo response rates than placebo-
controlled trials [48]. Comparator trials are ethically eas-
ier to defend than placebo-controlled trials because they
provide treatment for more patients [48]. Further, be-
cause superiority of active medication may be easier to
achieve over inactive placebo than over competing medi-
cation, placebo-controlled trials may allow drugs into
the marketplace that are less efficacious than those
already available [49]. Our goal here was conservative; to
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was non-inferior to Artz, because Artz has a long record
of safety and efficacy in China. A placebo arm would
have increased costs substantially, while providing no
greater clarity as to whether Durolane is comparable
with the established treatment option.
The relative merits of one injection versus five injec-
tions are an important issue for physicians using HA to
treat knee OA. Patients might prefer to have one injec-
tion, if they could be certain that one injection was as ef-
fective as five injections. Such a preference could be
driven by considerations such as pain of multiple injec-
tions and inconvenience of multiple clinic visits. How-
ever, physicians might prefer to give five injections, for
several reasons: multiple patient visits give the physician
more opportunity to monitor the patient over time and
to address AEs that might otherwise go unaddressed;
and the adverse consequences of accidentally missing
the joint space in a single injection are minimized if the
patient is scheduled to receive additional injections.
How these considerations influence physician choice of
medications is a topic that should be addressed in future
research.
Conclusions
We found that both Durolane and ARTZ were effective:
more than 90% of all patients reported a favorable re-
sponse by OMERACT-OARSI criteria over time periods
as long as 18 and 26 weeks (Table 3); at least 92% of pa-
tients had a decrease in pain while walking on a flat sur-
face (Table 3); and more than 77% of patients reported a
decrease in symptoms assessed by the WOMAC pain
subscale (Table 3). These results demonstrate that one
injection of Durolane and five injections of ARTZ are
comparably safe, effective, and well-tolerated treatments
for mild to moderate knee OA.
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